This series on The Evolving Landscape of Neoadjuvant Systemic Treatments in Breast Cancer is edited by Dr. Yoon-Sim Yap, MBBS, PhD, FRACP from Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Yoon-Sim Yap, MBBS, PhD, FRACP
Division of Medical Oncology, National Cancer Centre Singapore, Singapore
Dr. Yap is Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore, and Associate Professor at Duke-National University Singapore.
A recipient of the Singapore National Medical Research Council (NMRC) Clinician Scientist Award (CSA), her research focuses primarily on clinical and translational research in breast cancer, including liquid biopsies and predictive biomarkers, development of novel therapeutic strategies, and epidemiologic studies on treatment outcomes in breast cancer. She is the principal investigator of several phase 1 to 3 clinical trials for various compounds such as CDK inhibitors, PI3K and mTOR inhibitors, selective estrogen receptor degraders, and HER2-targeting agents, in addition to investigator-initiated studies.
- Neoadjuvant endocrine therapy in breast cancer - who, when and how?
- Optimizing response to neoadjuvant chemotherapy in luminal breast cancer
- Triple negative breast cancer: Recent breakthroughs in triple negative breast cancer
- HER2+ breast cancer: Is there still room for improvement in HER2+ breast cancer?
- Translational: Promising biomarkers for tailoring neoadjuvant systemic therapies in breast cancer
- Challenges of radiotherapy post-neoadjuvant systemic therapy
- Surgical considerations after neoadjuvant systemic therapy
- Pathological assessment pre- and post- neoadjuvant therapy - the basics and beyond
- Role of imaging in neoadjuvant systemic therapy
The series “Patient-associated Features and Breast Cancer” was commissioned by the editorial office, Annals of Breast Surgery without any sponsorship or funding. Dr. Yoon-Sim Yap is serving as the unpaid Guest Editor for the series.